An interventional study of Nasal humidified heated high flow cannula (NHHHC) and Nasal intermittent positive pressure ventilation (NIPPV) in Preterm and Ventilator Lung; Newborn, sponsored by Alexandria University. Recruiting at 1 site in Egypt. Open to participants aged 1 Hour to 24 Hours, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Alexandria University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Premature Birth by Alexandria University — 5 open to participants now, 5 under way, none of them phase 3. Premature Birth · Alexandria University.
Among the 10 studies in Premature Birth by Alexandria University, this one is the 10th largest by planned enrollment, is one of 3 that started in 2024, is one of 8 with no phase, and was the 6th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →5 of the 10 studies in Premature Birth by Alexandria University are open now, in 1 country. Recruiting first, the newest first:
Alexandria University · Sites in Egypt
Ages 3 days–1 mo
Alexandria University · Sites in Egypt
Ages 1 min–2 min · Healthy volunteers
Alexandria University · Sites in Egypt
Ages 1 hrs–3 days
Alexandria University
Ages 5 min–6 hrs
By country, each count listing its studies:
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 1 Hour to 24 Hours · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 100 across the 10 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Alexandria University is the lead sponsor of 610 studies on the registry; 143 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Premature Birth by Alexandria University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07896824Alexandria UniversityThe Hemodynamic Impact of High-frequency Oscillatory Ventilation and Periodic Sighs in Preterm Infants | 2027-11-15 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Premature Birth by Alexandria University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate the effect of non-invasive ventilation (nIPPV)
, (nCPAP), and nasal high flow cannula (NHFC) as a primary mode of ventilation in preterm neonates \<37 gestational week with moderate to severe RD using LUS as regard: I. Primary outcomes: Duration of non-Invasive ventilation. II. Secondary outcomes: Evaluation LUS over the 1 st 7 days of life or weaning from ventilation. Need for intubation and invasive ventilation. Duration of respiratory support. Need for surfactant. Oxygen saturation index and oxygen index. Broncho-pulmonary dysplasia; grade. Duration of hospital stay
Inclusion Criteria: Preterm \<37 wk. gestational age admitted to the NICU with spontaneous breathing and clinical manifestations of RD (tachypnea, nasal flaring, intercostal and subcostal retraction and or grunting).
Exclusion Criteria:
Device: Nasal intermittent positive pressure ventilation (NIPPV) · Device: lung ultrasound
Device: Nasal continuous positive airway pressure NCPAP · Device: lung ultrasound
Device: Nasal humidified heated high flow cannula (NHHHC) · Device: lung ultrasound
Patients in this arm will receive humidified heated high flow using Vapotherm device, USA. Stating with 2 L/min flow and increase gradually till 8L/minute, guided by oxygen requirements.
Patients in this arm will receive both PEEP (positive end expiratory pressure ) and PIP (peak inspiratory pressure) using SLE 5000/6000 device, UK . Pressures will be adjusted according to severity of respiratory distress.
Patients in this arm will receive PEEP (positive end expiratory pressure ), stating from 5 mbar to reach maximally 8 mbar.
Lung ultrasound (LUS) machine is a mobile device (Philips HDll XE, USA) with s8-3 probe with a frequency range of 8-3 MHz will be used as ultrasound machine. Throughout the period of non-invasive respiratory support Patient will be monitored by: LUS,Heart rate, Respiratory rate, Mean arterial pressure, Oxygen saturation index, Oxygen index, PaO2, blood gases and Fractional inspired oxygen (Fio2).
Duration of non-Invasive ventilation (NIV)
Describe the days of non-invasive ventilation , described in days number.
Time frame: First two weeks of life.
Oxygen saturation index (OSI).
Mean airway pressure (MAP)X Fraction of inspired oxygen (FIO2) X SPO2 ( oxygen saturation) The score of OSI is recorded twice per day for first seven days.
Time frame: first one weeks of life.
Started Nov 2024 (actual). Primary completion is estimated for May 2025, 6 months after the start.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 6 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.